Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—concluding thoughts
Ce dossier présente un ensemble d'articles analysant les facteurs associés au risque de nausées et vomissements induits par la chimiothérapie, et évaluant la prévention et la prise en charge de ces effets indésirables chez les patients atteints de cancer
Significant progress has been made in the search for perfection regarding management of chemotherapy-induced nausea and vomiting (CINV) in patients with cancer. As our understanding of the physiologic aspects of this complex side effect expands, new targets and novel antiemetic therapies will continue to emerge. The substantial gains achieved with the introduction of 5-hydroxytryptamine (5-HT3) and neurokinin-1 (NK-1) receptor antagonists provide evidence that these physiologic insights can be translated into active therapies that improve patient care [1]. Strategies for CINV prevention and management will undoubtedly continue to evolve as the treatment landscape for cancer steadily advances. The demand for more effective, better tolerated cancer therapy continues to drive development of novel chemotherapeutic agents and targeted therapies. The emetogenic potential of these novel agents vary greatly, with many emerging therapies not yet classified or included in current antiemetic guidelines [2, 3, 4]. Oral chemotherapeutic agents and targeted therapies are often administered daily for extended periods of time, requiring special considerations for prevention of treatment-related nausea and vomiting [5].